POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be removed by surgery. Pembrolizumab helps the immune system attack cancer cells, while lenvati…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New combo aims to shrink tough tumors
Disease control Recruiting nowThis early-stage study tests a new two-drug combination for people with advanced colorectal or gastroesophageal cancer that has spread. The goal is to find the safest dose and see how well the drugs work together to stop tumor growth. About 45 participants will take part.
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC